Super Human Blend (CJC-1295 + Ipamorelin + BPC-157 + TB-500)
The Super Human Blend is a compounded four-peptide combination of CJC-1295 (GHRH analog), Ipamorelin (GH secretagogue), BPC-157 (tissue repair peptide), and TB-500 (thymosin beta-4 fragment). The protocol combines growth hormone secretagogues with healing peptides for a multi-pathway approach to recovery, body composition, and regeneration.
The Super Human Blend is a compounded multi-peptide formulation combining four peptides with complementary mechanisms: CJC-1295 (a growth hormone-releasing hormone analog), Ipamorelin (a growth hormone secretagogue), BPC-157 (a tissue repair peptide), and TB-500 (a thymosin beta-4 fragment). The rationale for this combination is to simultaneously stimulate endogenous growth hormone release while providing direct tissue repair and regenerative support through parallel healing pathways.
Overview
The Super Human Blend combines two categories of peptides: growth hormone secretagogues (CJC-1295 + Ipamorelin) and tissue repair peptides (BPC-157 + TB-500). Each pair has established synergy within its category, and the combination protocol seeks to leverage cross-category benefits -- using GH axis stimulation to amplify the healing effects of tissue repair peptides, while the repair peptides support the structural recovery needed to benefit fully from GH-mediated anabolism.
CJC-1295 stimulates growth hormone release from the pituitary by activating GHRH receptors, while Ipamorelin acts through the ghrelin/GHS receptor pathway. Together, they produce amplified GH pulses through dual-receptor activation. BPC-157 promotes angiogenesis and fibroblast recruitment via VEGFR2 signaling, while TB-500 enhances cell migration through actin regulation. Together, they address both vascular supply and cellular mobilization components of wound healing.
This blend is available through compounding pharmacies as either a pre-mixed vial or as separate vials to be combined by the end user. No clinical trials have evaluated the specific four-peptide combination, and the rationale rests on the established mechanisms and preclinical data for each component individually and in pairs.
Mechanism of Action
GH Secretagogue Component
- CJC-1295 (GHRH pathway): Binds to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and secretion through cAMP-PKA signaling. Provides the "release signal" for GH synthesis and pulse initiation
- Ipamorelin (GHS-R1a pathway): Activates ghrelin receptors on the pituitary and hypothalamus, amplifying GH pulses through phospholipase C / calcium signaling. Suppresses somatostatin release, extending GH pulse duration. Selective for GH release -- does not significantly elevate cortisol, ACTH, or prolactin unlike GHRP-6 or GHRP-2
Tissue Repair Component
- BPC-157 (angiogenesis/VEGFR2): Upregulates VEGFR2 expression and stimulates fibroblast proliferation and migration, promoting angiogenesis and extracellular matrix deposition at injury sites
- TB-500 (cell migration/actin): Sequesters G-actin monomers to regulate F-actin polymerization, facilitating cell migration and tissue repair through enhanced motility of fibroblasts, endothelial cells, and immune cells
Cross-Category Synergy
The GH secretagogue and tissue repair components may interact synergistically through several mechanisms:
- GH and IGF-1 elevation amplifies fibroblast proliferation and collagen synthesis, potentially enhancing BPC-157 and TB-500's repair effects
- BPC-157 upregulates growth hormone receptor expression on fibroblasts (Chang et al., 2014), potentially increasing tissue responsiveness to the GH/IGF-1 elevated by CJC-1295/Ipamorelin
- TB-500 provides the actin-dependent cell migration infrastructure needed for GH receptor-expressing fibroblasts to reach wound sites
Reconstitution Calculator
Super Human Blend (CJC-1295 + Ipamorelin + BPC-157 + TB-500)
The Super Human Blend is a compounded multi-peptide formulation combining four p
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
CJC-1295 + Ipamorelin Synergy
The combination of GHRH-pathway and GHS-R1a-pathway stimulation produces greater GH release than either peptide alone. This synergy is well-established: GHRH provides the primary secretory stimulus while GHS amplify the response by suppressing somatostatin-mediated inhibition. Research demonstrates that concurrent GHRH + GHS administration produces GH pulses 2-3 times larger than the sum of individual responses.
BPC-157 + TB-500 Synergy
BPC-157 and TB-500 target complementary aspects of wound healing. BPC-157 promotes blood vessel growth (angiogenesis) and fibroblast recruitment through VEGFR2, while TB-500 enhances cell migration through actin regulation. Together, they provide both the vascular supply and cellular mobilization needed for tissue repair. See BPC-157/TB-500 Blend for detailed combination research.
Growth Hormone and Tissue Repair
Endogenous GH and IGF-1 are established mediators of tissue repair. GH-deficient individuals show impaired wound healing, and GH replacement accelerates healing rates. The rationale for combining GH secretagogues with repair peptides is that elevating the GH/IGF-1 axis creates a more anabolic systemic environment that supports the localized tissue repair promoted by BPC-157 and TB-500.
Safety Profile
The safety profile of the Super Human Blend is based on the individual components, as no formal safety studies exist for the four-peptide combination:
- CJC-1295: Flushing, headache, dizziness at injection time (transient). Theoretical concerns about sustained IGF-1 elevation with chronic use.
- Ipamorelin: Generally well-tolerated. Transient headache, flushing. Minimal effect on cortisol and prolactin (advantage over GHRP-2/GHRP-6).
- BPC-157: No reported toxicity in preclinical studies across wide dose ranges. No human clinical trial safety data.
- TB-500: Limited safety data. Theoretical concerns about proliferative effects in the context of active malignancy.
- Combined: No drug interaction data for the four-peptide combination. The shared GH-stimulatory and angiogenic properties raise theoretical concerns that have not been formally evaluated.
- Compounding quality: As a compounded product, stability and purity depend on the compounding pharmacy's practices.
Pharmacokinetic Profile
Super Human Blend (CJC-1295 + Ipamorelin + BPC-157 + TB-500) — Pharmacokinetic Curve
Subcutaneous injectionQuick Start
- Typical Dose
- 300mcg
- Route
- Subcutaneous injection
- Storage
- Refrigerate 2-8°C
Research Protocols
subcutaneous Injection
Subcutaneous injection
Interactions
Peptide Interactions
The combination of GHRH-pathway and GHS-R1a-pathway stimulation produces greater GH release than either peptide alone. This synergy is well-established: GHRH provides the primary secretory stimulus while GHS amplify the response by suppressing somatostatin-mediated inhibition. Research demonstrat...
BPC-157 and TB-500 target complementary aspects of wound healing. BPC-157 promotes blood vessel growth (angiogenesis) and fibroblast recruitment through VEGFR2, while TB-500 enhances cell migration through actin regulation. Together, they provide both the vascular supply and cellular mobilization...
The Super Human Blend is a compounded multi-peptide formulation combining four peptides with complementary mechanisms: CJC-1295 (a growth hormone-releasing hormone analog), Ipamorelin (a growth hormone secretagogue), BPC-157 (a tissue repair peptide), and TB-500 (a thymosin beta-4 fragment).
The Super Human Blend is a compounded multi-peptide formulation combining four peptides with complementary mechanisms: CJC-1295 (a growth hormone-releasing hormone analog), Ipamorelin (a growth hormone secretagogue), BPC-157 (a tissue repair peptide), and TB-500 (a thymosin beta-4 fragment).
The Super Human Blend is a compounded multi-peptide formulation combining four peptides with complementary mechanisms: CJC-1295 (a growth hormone-releasing hormone analog), Ipamorelin (a growth hormone secretagogue), BPC-157 (a tissue repair peptide), and TB-500 (a thymosin beta-4 fragment).
What to Expect
What to Expect
Rapid onset expected; half-life of CJC-1295: ~30 min (no DAC) / ~8 days (DAC); Ipamorelin: ~2 hours; BPC-157: ~4 hours; TB-500: ~6-8 hours indicates...
Due to short half-life (CJC-1295: ~30 min (no DAC) / ~8 days (DAC); Ipamorelin: ~2 hours; BPC-157: ~4 hours; TB-500: ~6-8 hours), effects are...
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Human clinical trials conducted
- Well-established safety profile
Frequently Asked Questions
References (6)
- [1]Hsieh MJ et al Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation J Mol Med (2017)
- [2]Philp D et al Thymosin beta4 increases hair growth by activation of hair follicle stem cells FASEB J (2004)
- [3]Chang CH et al BPC-157 enhances the growth hormone receptor expression in tendon fibroblasts Molecules (2014)
- [4]Teichman SL et al Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 J Clin Endocrinol Metab (2006)
- [5]
- [6]Chang CH et al BPC-157 promotes tendon outgrowth, cell survival, and cell migration J Appl Physiol (2010)
Substance P
Substance P is an 11-amino acid tachykinin neuropeptide that functions as a key neurotransmitter in pain transmission, neurogenic inflammation, and mood regulation through the neurokinin-1 (NK1) receptor. It is one of the most extensively studied neuropeptides and the target of NK1 receptor antagonists used clinically as antiemetics.
Super Shred (AOD-9604 + CJC-1295 + Ipamorelin)
The Super Shred blend is a compounded three-peptide fat loss stack combining AOD-9604 (anti-obesity GH fragment), CJC-1295 (GHRH analog), and Ipamorelin (GH secretagogue). The protocol targets body recomposition through direct lipolytic action and enhanced growth hormone secretion for simultaneous fat loss and lean mass preservation.